about
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortiumEpithelial ovarian cancer - more data, more questions?Linking the ovarian cancer transcriptome and immunomeAssociation of myeloperoxidase with ovarian cancer.Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patientsFive genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues.Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer.Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumIn ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways.Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortiumAmbivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo.Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.Methylation status of TUSC3 is a prognostic factor in ovarian cancer.Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation.hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.Oncogenic BARD1 isoforms expressed in gynecological cancers.Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals.Characterization of three bioenergetically active respiratory terminal oxidases in the cyanobacterium Synechocystis sp. strain PCC 6803.Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.Respiratory terminal oxidases in the facultative chemoheterotrophic and dinitrogen fixing cyanobacterium Anabaena variabilis strain ATCC 29413: characterization of the cox2 locus.Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.Cytochrome c oxidase genes required for nitrogenase activity and diazotrophic growth in Anabaena sp. PCC 7120.Long-acting beneficial effect of percutaneously intramyocardially delivered secretome of apoptotic peripheral blood cells on porcine chronic ischemic left ventricular dysfunction.Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD ConsortiumCommon death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancerPromoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevanceNeutrophil Extracellular Trap Formation Correlates with Favorable Overall Survival in High Grade Ovarian CancerThe Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue MicroarrayImmunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile
P50
Q28275893-39B1B6FF-C9A0-405D-BDC0-553935064DE8Q30869183-16E6C0BE-E5AE-4F3A-9BDF-8344E207FCD4Q33313203-B1F380A3-5049-41EB-99B8-D6C8264F548EQ33689246-0064D82B-07BF-4A53-ABF2-938D7BA94548Q33772182-DFD5793E-62BA-42B4-9913-386C783F13FEQ34465346-6D946B2A-A1F0-494B-8754-DB0B647432F6Q34646749-620E666E-60A2-4612-A07E-C181643319AAQ35015274-F90302AF-7EB8-4B02-9DBD-88D5DDBA555FQ35803334-24E6B10E-D590-4305-AAC4-5AD32BB0D429Q36498614-620F7728-B31A-416F-9259-69A90B250333Q36609813-45718CE8-6306-400E-B067-2C2449732302Q36940317-A812B915-3ABD-457F-ADC5-BE3343D4F2AEQ37359509-FCF38A2C-6579-467E-B1EC-50508F720E77Q37720579-EED32450-A4C2-43D6-9647-901CE34282E0Q38904136-E4A47163-A0A6-46AC-B802-A6DF1918C63FQ39033641-ECF6EEA4-8128-4866-B991-8B46D6E4A4A9Q39195368-79F0B9F8-5670-43FA-B884-A1BF07CAA2EDQ39253858-A34DBE46-0F8B-4F5B-BB0D-5FB69CD9E3D1Q39415443-53EBCC42-697D-43F0-8722-D612BE79E136Q39455024-0E6D885D-1AB2-4C9D-A244-1BAB1184F64AQ39734268-28E9E796-9393-4422-810C-5A6A8DD2B743Q40033549-BD6A468E-603A-46E0-BFF1-98E5FB865395Q40364302-2DE1E278-41EC-4F5B-9158-26024598614CQ40405998-520DE073-9E1A-4C5D-ACE4-D0AD9EC08650Q40533876-C13F8FDB-0F98-4F81-B334-CEAC6B3A506AQ42258630-F5D4CBF4-9284-478E-941B-E9A47CB12106Q42491728-73CF8625-63FD-4A00-822F-03225D7637FFQ43033143-AAE581BC-2B4C-49C0-AC19-E9358016C9B0Q43754664-BC278011-0582-4271-8235-C553930A5BFEQ44832302-3EA7EA51-91EB-4214-AF22-3522ECA3DBF9Q45129024-B9489EF8-3713-4D3C-A384-EB434B4F55B3Q45265038-A45CCF08-40AD-4A2D-A730-E7FEBD3560DEQ51684753-B2A06166-FEDD-4E8C-8F84-C6B87F88C203Q54227366-1760E6D2-6D3D-43ED-A5D3-9237CDE82087Q61853673-FB2601E0-7F8B-4F90-B2E0-C43852862D18Q61853694-247E0356-7A56-47A8-92BC-CFB4F3223BF1Q79456929-90B63122-0F45-4DAE-A359-5CB537C97962Q89879464-EEEA26E3-06BA-4355-B300-DBA81F609812Q89977273-8E66537E-DDA9-4779-9A9B-D4AD95067218Q91324155-B2607EF2-CFF0-4A81-960D-AB40ADB95A1A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dietmar Pils
@ast
Dietmar Pils
@en
Dietmar Pils
@es
Dietmar Pils
@nl
Dietmar Pils
@sl
type
label
Dietmar Pils
@ast
Dietmar Pils
@en
Dietmar Pils
@es
Dietmar Pils
@nl
Dietmar Pils
@sl
prefLabel
Dietmar Pils
@ast
Dietmar Pils
@en
Dietmar Pils
@es
Dietmar Pils
@nl
Dietmar Pils
@sl
P106
P21
P31
P496
0000-0002-8355-0977